Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2/3 study assessing MH002

Next Previous
Trial Profile

Phase 2/3 study assessing MH002

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 17 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MH 002 (Primary)
  • Indications Pouchitis; Ulcerative colitis
  • Focus Therapeutic Use

Most Recent Events

  • 16 Apr 2024 According to MRM Health media release, based on the combined results from both clinical trials and recent positive feedback from regulatory authorities, the Company is in the position to initiate Phase 2/3 development in Ulcerative Colitis, to be combined with further development in Pouchitis.
  • 21 Sep 2023 New trial record
  • 19 Sep 2023 According to MRM Health media release, the company has initiated to progress the program into this Phase 2/3 development.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top